The new company will allow Merck to focus on its larger products, such as the cancer drug Keytruda. It plans to reduce the number of human health products it makes and sells by about 50 percent.
The yet-to-be-named company will allow Merck to save $1.5 billion by 2024, the company predicted. It expects the deal to close in the first half of 2021.
Merck will keep its oncology products, vaccines, hospital and animal health products, while its women’s health, legacy brands and biosimilars will go to the new company.
Read the full news release here.
More articles on pharmacy:
Walgreens pays $7.5M to resolve claims an employee impersonated a pharmacist
SwedishAmerican opens ScriptCenter, a self-serve pharmacy kiosk
Walgreens CEO talks strategy, skips buyout speculation at annual meeting
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
